Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.
Abdel-Wahab O, Klimek VM, Gaskell AA, Viale A, Cheng D, Kim E, Rampal R, Bluth M, Harding JJ, Callahan MK, Merghoub T, Berger MF, Solit DB, Rosen N, Levine RL, Chapman PB. Abdel-Wahab O, et al. Among authors: klimek vm. Cancer Discov. 2014 May;4(5):538-45. doi: 10.1158/2159-8290.CD-13-1038. Epub 2014 Mar 3. Cancer Discov. 2014. PMID: 24589925 Free PMC article.
Systemic chemotherapy.
Klimek VM, Wolchok JD, Chapman PB, Houghton AN, Hwu WJ. Klimek VM, et al. Clin Plast Surg. 2000 Jul;27(3):451-61, ix-x. Clin Plast Surg. 2000. PMID: 10941565 Review.
T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants.
Schaed SG, Klimek VM, Panageas KS, Musselli CM, Butterworth L, Hwu WJ, Livingston PO, Williams L, Lewis JJ, Houghton AN, Chapman PB. Schaed SG, et al. Among authors: klimek vm. Clin Cancer Res. 2002 May;8(5):967-72. Clin Cancer Res. 2002. PMID: 12006508 Clinical Trial.
Progression of RAS-mutant leukemia during RAF inhibitor treatment.
Callahan MK, Rampal R, Harding JJ, Klimek VM, Chung YR, Merghoub T, Wolchok JD, Solit DB, Rosen N, Abdel-Wahab O, Levine RL, Chapman PB. Callahan MK, et al. Among authors: klimek vm. N Engl J Med. 2012 Dec 13;367(24):2316-21. doi: 10.1056/NEJMoa1208958. Epub 2012 Nov 7. N Engl J Med. 2012. PMID: 23134356 Free PMC article.
Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia.
Coombs CC, Sallman DA, Devlin SM, Dixit S, Mohanty A, Knapp K, Al Ali NH, Lancet JE, List AF, Komrokji RS, Padron E, Arcila ME, Klimek VM, van den Brink MR, Tallman MS, Levine RL, Rampal RK, Rapaport F. Coombs CC, et al. Among authors: klimek vm. Haematologica. 2016 Nov;101(11):e457-e460. doi: 10.3324/haematol.2016.148999. Epub 2016 Jul 14. Haematologica. 2016. PMID: 27418649 Free PMC article. No abstract available.
CD99 is a therapeutic target on disease stem cells in myeloid malignancies.
Chung SS, Eng WS, Hu W, Khalaj M, Garrett-Bakelman FE, Tavakkoli M, Levine RL, Carroll M, Klimek VM, Melnick AM, Park CY. Chung SS, et al. Among authors: klimek vm. Sci Transl Med. 2017 Jan 25;9(374):eaaj2025. doi: 10.1126/scitranslmed.aaj2025. Sci Transl Med. 2017. PMID: 28123069 Free PMC article.
69 results